Poliovirus Receptor anticorps (FITC)

N° du produit ABIN2853601

Cet anticorps Rat Monoclonal détecte spécifiquement Poliovirus Receptor dans FACS. Il présente une réactivité envers Humain.

Aperçu rapide pour Poliovirus Receptor anticorps (FITC) (ABIN2853601)

Antigène: Poliovirus Receptor (PVR)

Reactivité: Humain

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp Poliovirus Receptor est conjugé à/à la FITC

Application: Flow Cytometry (FACS)

Clone: TX21

Détail du produit anti-Poliovirus Receptor anticorps (FITC)

Specificité: This antibody reacts with human CD155.

Purification: Protein G agarose

Immunogène: Recombinant human CD155

Isotype: IgG2a

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: PBS, 0.09 % NaN3, 1 % BSA

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store at 2-8 °C.

Détails sur Poliovirus Receptor

Antigène: Poliovirus Receptor (PVR)

Autre désignation: CD155 / PVR

Sujet: CD155, transmembrane glycoprotein, is a member of the immunoglobulin superfamily also known as the human receptor for poliovirus (PVR). CD155 localizes in cell-matrix adhesions and cell-cell junctions. PV receptor CD155 forms a complex with PV (PV1, PV2, and PV3). Both glycosylated and fully deglycosylated CD155 exhibited similar binding sites and orientations in the viral canyon for all three PV serotypes, showing that all three serotypes use a common mechanism for cell entry. It is reported that CD155 and CD112/nectin-2/PRR-2 are ligands of CD226/DNAM-1.Synonyms: Necl-5, Necl5, Nectin-like protein 5, PVS, Poliovirus receptor

ID gène: 5817

NCBI Accession: NP_001129240

UniProt: P15151

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Cancer Immune Checkpoints, SARS-CoV-2 Protein Interactome